Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial

BACKGROUND: Association of immune-related adverse events with tumor response has been reported. Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common adverse event related to camrelizumab, an immune checkpoint inhibitor, but lack of comprehensive analyses. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Feng, Qin, Shukui, Sun, Xinchen, Ren, Zhenggang, Meng, Zhiqiang, Chen, Zhendong, Chai, Xiaoli, Xiong, Jianping, Bai, Yuxian, Yang, Lin, Zhu, Hong, Fang, Weijia, Lin, Xiaoyan, Chen, Xiaoming, Li, Enxiao, Wang, Linna, Yan, Ping, Zou, Jianjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216554/
https://www.ncbi.nlm.nih.gov/pubmed/32393323
http://dx.doi.org/10.1186/s13045-020-00886-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216554/
https://www.ncbi.nlm.nih.gov/pubmed/32393323
http://dx.doi.org/10.1186/s13045-020-00886-2

Ejemplares similares